<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841734</url>
  </required_header>
  <id_info>
    <org_study_id>18-AOIP-01</org_study_id>
    <nct_id>NCT03841734</nct_id>
  </id_info>
  <brief_title>Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO</brief_title>
  <acronym>CECIBO</acronym>
  <official_title>Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giant cell arteritis , also named Horton's disease, is the most common vasculitis in subjects
      over 50 years old. The incidence increases with age : from 188 to 290 cases per million
      inhabitants per year, with a North-South gradient.

      The major risk of Horton's disease is blindness, unilateral, occurring in 15 to 20% of cases,
      sometimes preceded by episodes of transient amaurosis. The decrease in visual acuity is often
      brutal, irreversible and bilateral in 25 to 50% of cases. The mechanism of this blindness is
      an arterial ischemia: Acute Anterior Ischemic Optic Neuropathy acute anterior ischaemic optic
      neuropathy (90%), acute retro-bulbar ischaemic optic neuropathy (5%), occlusion of the
      central artery of the retina (5%).

      The pathogenesis of this brutal ischemia is not fully understood. One of the hypotheses
      suggests that, during stimulation by an antigen of the environment, preactivated dendritic
      cells of the arterial wall would stimulate T lymphocytes. These will recruit cells that cause
      an inflammatory infiltrate polymorphic predominant at the media level. These lesions may be
      accompanied by destruction of the internal elastic lamina, with inconstant but pathognomonic
      presence of multinucleated giant cells. All arteries with internal elastic lamina can be
      affected by parietal inflammation, which results in stenosis and occlusion, explaining the
      ischemia.

      The visual loss is usually abrupt and very severe, leaving the patient with definitely very
      low or no residual visual acuity.

      Conventional treatment currently recommended includes systemic corticosteroid therapy at 1 mg
      / kg / day, preceded or not by 500 mg pulses of methylprednisolone , and associated with
      antiplatelet and anticoagulant therapy (LMWH). Despite the decline in visual acuity thus
      occurred is then always final. Certainly loss of vision has a major impact on the quality of
      life of patients.

      Apart from this lymphocytic inflammation, a process of vascular remodeling is at the origin
      of the vascular occlusion phenomenon. The endothelin system is a family of amino acids
      including 3 members: ET1, ET2 and ET3. ET1 is a potent vasoconstrictor. ET1 receptors (ETA
      and ETB) are expressed in the arteries of patients with giant cell arteritis . The expression
      of ET1 associated with proliferation of muscle cells in arteries will decrease under the
      effect of endothelin inhibitors. This has been shown during treatment of pulmonary
      hypertension. In giant cell arteritis , the endothelin system continues to be very active up
      to 8 days despite the introduction of systemic corticosteroids. Bosentan is a mixed
      endothelin receptor antagonist with affinity for both ETA and ETB receptors. This inhibitor
      is used in treatment of pulmonary artery hypertension, digital ulcerations of systemic
      sclerosis and critical peripheral arterial ischemia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity calculated according to the Early Treatment Diabetic Retinopathy Study</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity calculated according to the Early Treatment Diabetic Retinopathy Study</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goldman's one-sided visual field</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of adverse event and serious adverse events</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Arteritis, Giant Cell</condition>
  <condition>Blindness and Low Vision</condition>
  <arm_group>
    <arm_group_label>Treatment bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treatment</intervention_name>
    <description>8 patients will be treat with bosentan at 145 mg per day during 14 days</description>
    <arm_group_label>Treatment bosentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Decreased visual acuity (BVA) &lt;5 days, regardless of degree of severity, abrupt onset
             in the context of newly diagnosed or suspected Horton's disease at this loss of visual
             acuity

          -  Able to sign the consent

          -  Affiliated to the social security system

          -  Already under conventional treatment of Horton's disease or the: requiring:
             Corticosteroids and + - anti-platelet aggregators and / or LMWH at the discretion of
             the referring physician for its vasculitis and + - immunosuppressive or biotherapy if
             necessary.

        Exclusion Criteria:

          -  Underlying hepatocellular insufficiency known

          -  Patient under guardianship or curator

          -  Hypersensitivity to the active substance or to any of the excipients

          -  Moderate to severe hepatic insufficiency corresponding to class B or C of the
             Child-Pugh classification

          -  Any other ophthalmological pathology explaining the sudden drop in vision: retinal
             detachment, retinal hemorrhage, posterior uveitis, nonarteritic arterial occlusion,
             cortical stroke

          -  Serum levels of hepatic aminotransferases, aspartate aminotransferases (ASTs) and / or
             alanine aminotransferases (ALATs), greater than 3 times the upper limit of normal
             before start of treatment

          -  Patient under treatment with cyclosporine A, antiretrovirals, glibenclamide or
             Rifampicin.

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Tieulié, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Tieulié, MD</last_name>
    <phone>04 92 03 90 19</phone>
    <email>tieulie.n@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH de Cannes</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lea Blanchouin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Chaigne-Delalande S, de Menthon M, Lazaro E, Mahr A. [Giant-cell arteritis and Takayasu arteritis: epidemiological, diagnostic and treatment aspects]. Presse Med. 2012 Oct;41(10):955-65. doi: 10.1016/j.lpm.2012.07.011. Epub 2012 Aug 31. Review. French.</citation>
    <PMID>22940467</PMID>
  </reference>
  <reference>
    <citation>Watelet B, Samson M, de Boysson H, Bienvenu B. Treatment of giant-cell arteritis, a literature review. Mod Rheumatol. 2017 Sep;27(5):747-754. doi: 10.1080/14397595.2016.1266070. Epub 2017 Jan 13. Review.</citation>
    <PMID>27919193</PMID>
  </reference>
  <reference>
    <citation>Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008 Jul 19;372(9634):234-45. doi: 10.1016/S0140-6736(08)61077-6. Review.</citation>
    <PMID>18640460</PMID>
  </reference>
  <reference>
    <citation>González-Gay MA, García-Porrúa C, Llorca J, Hajeer AH, Brañas F, Dababneh A, González-Louzao C, Rodriguez-Gil E, Rodríguez-Ledo P, Ollier WE. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000 Sep;79(5):283-92.</citation>
    <PMID>11039076</PMID>
  </reference>
  <reference>
    <citation>Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003 Jul 10;349(2):160-9. Review.</citation>
    <PMID>12853590</PMID>
  </reference>
  <reference>
    <citation>Bienvenu B, Ly KH, Lambert M, Agard C, André M, Benhamou Y, Bonnotte B, de Boysson H, Espitia O, Fau G, Fauchais AL, Galateau-Sallé F, Haroche J, Héron E, Lapébie FX, Liozon E, Luong Nguyen LB, Magnant J, Manrique A, Matt M, de Menthon M, Mouthon L, Puéchal X, Pugnet G, Quemeneur T, Régent A, Saadoun D, Samson M, Sène D, Smets P, Yelnik C, Sailler L, Mahr A; Groupe d’Étude Français des Artérites des gros Vaisseaux, under the Aegis of the Filière des Maladies Auto-Immunes et Auto-Inflammatoires Rares. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016 Mar;37(3):154-65. doi: 10.1016/j.revmed.2015.12.015. Epub 2016 Jan 29.</citation>
    <PMID>26833145</PMID>
  </reference>
  <reference>
    <citation>Weyand CM, Schönberger J, Oppitz U, Hunder NN, Hicok KC, Goronzy JJ. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med. 1994 Mar 1;179(3):951-60.</citation>
    <PMID>8113687</PMID>
  </reference>
  <reference>
    <citation>Terrades-Garcia N, Cid MC. Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved. Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii51-ii62. doi: 10.1093/rheumatology/kex423. Review.</citation>
    <PMID>29982777</PMID>
  </reference>
  <reference>
    <citation>Lozano E, Segarra M, Corbera-Bellalta M, García-Martínez A, Espígol-Frigolé G, Plà-Campo A, Hernández-Rodríguez J, Cid MC. Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Ann Rheum Dis. 2010 Feb;69(2):434-42. doi: 10.1136/ard.2008.105692. Epub 2009 Mar 15.</citation>
    <PMID>19289383</PMID>
  </reference>
  <reference>
    <citation>Dimitrijevic I, Andersson C, Rissler P, Edvinsson L. Increased tissue endothelin-1 and endothelin-B receptor expression in temporal arteries from patients with giant cell arteritis. Ophthalmology. 2010 Mar;117(3):628-36. doi: 10.1016/j.ophtha.2009.07.043. Epub 2009 Dec 24.</citation>
    <PMID>20036012</PMID>
  </reference>
  <reference>
    <citation>Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, Lozano E, Alba MA, Segarra M, Espígol-Frigolé G, Prieto-González S, Hernández-Rodríguez J, Preciado S, Lavilla R, Cid MC. Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. Ann Rheum Dis. 2017 Sep;76(9):1624-1634. doi: 10.1136/annrheumdis-2016-210792. Epub 2017 Jun 12.</citation>
    <PMID>28606962</PMID>
  </reference>
  <reference>
    <citation>Régent A, Ly KH, Groh M, Khifer C, Lofek S, Clary G, Chafey P, Baud V, Broussard C, Federici C, Labrousse F, Mesturoux L, Le Jeunne C, Vidal E, Brezin A, Witko-Sarsat V, Guillevin L, Mouthon L. Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. Autoimmun Rev. 2017 Apr;16(4):398-406. doi: 10.1016/j.autrev.2017.02.006. Epub 2017 Feb 14. Review.</citation>
    <PMID>28232168</PMID>
  </reference>
  <reference>
    <citation>Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan;70(1):32-8. doi: 10.1136/ard.2010.130658. Epub 2010 Aug 30.</citation>
    <PMID>20805294</PMID>
  </reference>
  <reference>
    <citation>Narváez J, García-Gómez C, Álvarez L, Santo P, Aparicio M, Pascual M, López de Recalde M, Borrell H, Nolla JM. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature. Medicine (Baltimore). 2016 Nov;95(48):e5511. Review.</citation>
    <PMID>27902617</PMID>
  </reference>
  <results_reference>
    <citation>Ly KH, Liozon E, Fauchais AL, Vidal E. [Pathophysiology of giant cell arteritis]. Rev Med Interne. 2013 Jul;34(7):392-402. doi: 10.1016/j.revmed.2013.02.037. Epub 2013 Mar 23. Review. French.</citation>
    <PMID>23528439</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

